Hikma Pharmaceuticals PLC
LSE:HIK
Intrinsic Value
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. [ Read More ]
The intrinsic value of one
HIK
stock under the Base Case scenario is
3 983.16
GBX.
Compared to the current market price of 1 913 GBX,
Hikma Pharmaceuticals PLC
is
Undervalued by 52%.
HIK could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Hikma Pharmaceuticals PLC's market capitalization is 4.2B GBX.
HIK stock price is 1 913 GBX.
HIK stock price (1913 GBX) is 52% less than its Intrinsic Value (3 983.16 GBX).
HIK stock price (1913 GBX) is 66% less than its Relative Value (5 545.83 GBX). Open Relative Valuation
HIK has upside potential of 23% compared to the average analyst price target.
Open Wall St Estimates
HIK's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 11%.
HIK's ROIC (Return on Invested Capital) has decreased in the last 3 years from 12% to 11%.
HIK's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
HIK has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
HIK has positive Net Income for the last twelve months.
HIK's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
HIK's Revenue has grown by 14% over the past 12 months.
HIK's Revenue has been growing by 7% per year for the last 3 years.
HIK has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
HIK's ROE (Return on Equity) has significantly decreased in the last 3 years from 20% to 9%.
HIK has positive Operating Income for the last twelve months.
HIK's Altman Z-Score is equal to 2.81.
HIK's short-term assets (2B USD) exceed its short-term liabilties (1B USD).
HIK has positive Free Cash Flow for the last twelve months.
HIK's long-term assets (5B USD) exceed its long-term liabilties (2B USD).
HIK has positive Gross Profit for the last twelve months.
HIK's D/E (Debt to Equity) is very low and is equal to 0.49.
HIK generates enough operating income (622m USD) to cover interest payments on its debt (82m USD).
HIK has positive Net Debt. This means that the company has more debt (1B USD) than cash and short-term investments (229m USD).
Valuation Backtest
Hikma Pharmaceuticals PLC
Run backtest to discover the historical profit from buying and selling
HIK
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Hikma Pharmaceuticals PLC
Balance Sheet Decomposition
Hikma Pharmaceuticals PLC
| Current Assets | 2.1B |
| Cash & Short-Term Investments | 229m |
| Receivables | 873m |
| Other Current Assets | 998m |
| Non-Current Assets | 2.6B |
| Long-Term Investments | 65m |
| PP&E | 1.1B |
| Intangibles | 1.1B |
| Other Non-Current Assets | 274m |
| Current Liabilities | 1.3B |
| Accounts Payable | 568m |
| Short-Term Debt | 46m |
| Other Current Liabilities | 725m |
| Non-Current Liabilities | 1.1B |
| Long-Term Debt | 1B |
| Other Non-Current Liabilities | 113m |
Earnings Waterfall
Hikma Pharmaceuticals PLC
|
Revenue
|
2.9B
USD
|
|
Cost of Revenue
|
-1.5B
USD
|
|
Gross Profit
|
1.4B
USD
|
|
Operating Expenses
|
-785m
USD
|
|
Operating Income
|
622m
USD
|
|
Other Expenses
|
-432m
USD
|
|
Net Income
|
190m
USD
|
Free Cash Flow Analysis
Hikma Pharmaceuticals PLC
HIK Profitability Score
Profitability Due Diligence
Hikma Pharmaceuticals PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Hikma Pharmaceuticals PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
HIK Solvency Score
Solvency Due Diligence
Hikma Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Hikma Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HIK Price Targets Summary
Hikma Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
HIK
is 2 347.53 GBX
with a low forecast of 1 898.8 GBX and a high forecast of 2 908.5 GBX.
Shareholder Return
HIK Price
Hikma Pharmaceuticals PLC
| Average Annual Return | 2.95% |
| Standard Deviation of Annual Returns | 25.9% |
| Max Drawdown | -54% |
| Market Capitalization | 4.2B GBX |
| Shares Outstanding | 221 884 992 |
| Percentage of Shares Shorted | 64% |
Company Profile
Hikma Pharmaceuticals PLC
Country
Industry
Market Cap
Dividend Yield
Description
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
Contact
IPO
Employees
Officers
The intrinsic value of one
HIK
stock under the Base Case scenario is
3 983.16
GBX.
Compared to the current market price of 1 913 GBX,
Hikma Pharmaceuticals PLC
is
Undervalued by 52%.
You don't have any saved screeners yet
